New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOvagen vs VIP

Ovagen vs VIP

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Ovagen
Immune SupportSleep Optimization
VIP
Summary
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
Admin Route
SubQ, Oral
Intranasal, SubQ, IV
Research
Typical Dose
10 mg per day
50 mcg (4 sprays of 12.5 mcg each)
Frequency
Daily for 10–30 days
4x daily
Key Benefits
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
  • Potent anti-inflammatory for CIRS and mold illness
  • Improves pulmonary hypertension symptoms
  • Regulates gut motility and IBS symptoms
  • Modulates circadian rhythm and sleep quality
  • Reduces mast cell activation (MCAS)
  • Improves cognitive function in neuroinflammatory conditions
  • Vasodilatory — reduces vascular resistance
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
  • Facial flushing (transient, intranasal)
  • Mild nausea
  • Headache at initiation
  • Hypotension at high doses
  • +1 more
Stacks With